SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

Abstract Background Glioblastoma is one of the most devastating cancer worldwide based on its locally aggressive behavior and because it cannot be cured by current therapies. Defects in alternative splicing process are frequent in cancer. Recently, we demonstrated that dysregulation of the spliceoso...

Full description

Bibliographic Details
Main Authors: Antonio C. Fuentes-Fayos, Jesús M. Pérez-Gómez, Miguel E. G-García, Juan M. Jiménez-Vacas, Cristóbal Blanco-Acevedo, Rafael Sánchez-Sánchez, Juan Solivera, Joshua J. Breunig, Manuel D. Gahete, Justo P. Castaño, Raúl M. Luque
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Glioblastoma
Splicing factor SF3B1
Glioma mouse models
Antitumor therapy
BCL2L1 splicing variants
Online Access:https://doi.org/10.1186/s13046-022-02241-4

Internet

https://doi.org/10.1186/s13046-022-02241-4

Similar Items